Significant therapeutic effectiveness of durvalumab after chemoradiotherapy for a patient with post‐operative recurrent pulmonary pleomorphic carcinoma

Significant therapeutic effectiveness of durvalumab after chemoradiotherapy for a patient with post‐operative recurrent pulmonary pleomorphic carcinoma

Abstract Pulmonary pleomorphic carcinoma (PPC) is a poorly differentiated non‐small cell lung cancer. Because of its rarity, no standard therapy has been established for advanced disease. We herein report on a 62‐year‐old man with recurrent post‐operative PPC, for whom durvalumab after chemoradiothe...

Full description

Bibliographic Details
Main Authors: So Shimamura, Masafumi Saiki, Shuichiro Ide, Kazuki Masuda, Yoshinori Uchida, Yusuke Sogami, Kazunari Kasai, Tomohiro Inoue, Hiroshi Ishihara
Format: Article
Language:English
Published: Wiley 2021-06-01
Series:Respirology Case Reports
Subjects:
Chemoradiotherapy
durvalumab
post‐operative recurrence
programmed cell death‐ligand 1
pulmonary pleomorphic carcinoma
Online Access:https://doi.org/10.1002/rcr2.781

Internet

https://doi.org/10.1002/rcr2.781

Similar Items